AUTL Stock Summary and Trading Ideas (Autolus Therapeutics PLC - American Depositary Shares | NASDAQ:AUTL)

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AUTL.

As of April 2, 2026, AUTL stock price climbed to $1.41 with 1,011,751 million shares trading.

AUTL has a beta of 1.49, meaning it tends to be more sensitive to market movements. AUTL has a correlation of 0.11 to the broad based SPY ETF.

AUTL has a market cap of $374.96 million. This is considered a Small Cap stock.

Last quarter Autolus Therapeutics PLC - American Depositary Shares reported $24 million in Revenue and -$.34 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.04.

In the last 3 years, AUTL traded as high as $7.45 and as low as $1.11.

The top ETF exchange traded funds that AUTL belongs to (by Net Assets): IBB, GWX, QQQS, IBBQ, BIB.

AUTL has underperformed the market in the last year with a price return of 0.0% while the SPY ETF gained +18.2%. AUTL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.1% and -2.8%, respectively, while the SPY returned -3.6% and -0.6%, respectively.

AUTL support price is $1.32 and resistance is $1.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUTL shares will trade within this expected range on the day.